Biovica, a Swedish biotech company, announces that it has received Laboratory Accreditation from the College of American Pathologists (CAP) for its Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory in San Diego, California. CAP accreditation is awarded to laboratories that meet stringent requirements and maintain the highest standards for laboratory operations of quality, accuracy, and consistency, as outlined by CAP.
CAP accreditation offers several commercial advantages. It facilitates the process of obtaining reimbursement from private insurance providers and enables DiviTum TKa expansion into New York, Maryland, and Washington D.C. Post license application and approval, Biovica will be able to offer DiviTum also in these locations and thereby be able to cover the entire US. In addition, CAP accreditation is a highly coveted credential, particularly among pharmaceutical and biotechnology companies. They seek it out when they require a more rigorous regulatory framework for their projects, especially when the data generated is intended for submission to the US Food and Drug Administration (FDA).
"I take great pride in the efforts put forth by our team to reach this significant milestone. Attaining CAP accreditation underscores our unwavering commitment to quality," says Warren Cresswell, president of the Americas at Biovica.
The College of American Pathology (CAP) was founded in 1961 in the United States for laboratory quality control and is one of the world's most prestigious accreditation bodies. Through an application process, CAP reviews and accredits laboratories across the United States to ensure these laboratories meet certain safety and patient care criteria, helping laboratories maintain the accuracy of test results, ensuring accurate patient diagnosis, and meeting required standards from CLIA, FDA, and OSHA. CAP accreditation is known as the gold standard for laboratory quality control worldwide and ensures that quality control standards strict enough to conduct testing for clinical diagnostic purposes.
Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica’s assay, DiviTum TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!